breast cancer
Conditions
Interventions
IMRT group:IMRT (breast + supraclavicular + internal mammary lymph node drainage area)
ALL-in-one group:ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18-70 years. 2. ECOG performance status of 0-2. 3. Newly diagnosed invasive breast cancer, underwent breast-conserving surgery plus axillary lymph node dissection, with positive axillary lymph nodes (ypN+) and negative surgical margins. 4. No distant metastasis. 5. Capable of tolerating radiotherapy. 6. For ER/PR-positive patients, willing to receive anticipated 5 years of endocrine therapy. 7. For HER2-positive patients, willing to receive anticipated 1 year of anti-HER2 targeted therapy. 8. For patients requiring neoadjuvant/adjuvant chemotherapy, must have completed chemotherapy. 9. Left ventricular ejection fraction (LVEF) measured by echocardiography is 50%. 10. Must undergo adjuvant IMRT (Intensity-Modulated Radiation Therapy). 11. Capable of tolerating lying still on the treatment accelerator bed for 30 minutes to complete All-In-One radiotherapy. 12. Have follow-up conditions and are willing to adhere to follow-up. 13. Signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Synchronous bilateral breast cancer; sentinel lymph node biopsy of the axilla was performed without axillary lymph node dissection. 2. Stage I breast reconstruction surgery or expander implantation surgery on the affected side chest wall. 3. The purpose of radiotherapy is palliative. 4. Myocardial infarction within the last 3 months or uncorrected unstable arrhythmia or uncorrected unstable angina. 5. History of chest wall or supraclavicular radiotherapy in the past; past or concurrent second primary malignant tumors (except for non-melanoma skin cancer, papillary/follicular thyroid carcinoma, and carcinoma in situ of the cervix). 6. All-in-one one-stop radiotherapy has not been completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence rate of adverse effects; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survical;disease free survival;cumulative internal mammary node recurrence;cumulative locoregional recurrence;distance metastasis;Contralateral non-invasive breast cancer, other secondary malignant tumors;major cardiovascular events;Life quality; | — |
Countries
China
Contacts
Public ContactZhen-Yu He
Sun Yat-sen University Cancer Center
Outcome results
None listed